FrancophonIA/ELRC3.0 huggingface dataset:
English: Data from the main study were also combined with data from a second ongoing study, and survival rates for 37 patients treated with Zalmoxis (23 from the main study and 14 from the ongoing study) were compared with rates from a patient database of 140 patients who have undergone haploidentical HSCT in the past.
Estonian: Põhiuuringu andmetele lisati teisest pooleliolevast uuringust pärit andmed ning seejärel võrreldi 37 Zalmoxisega ravitud patsiendi (23 põhiuuringust ja 14 teisest uuringust) elumust 140 patsiendi andmebaasist saadud elumuse näitajatega; neile 140 patsiendile oli varem tehtud haploidentne vereloome tüvirakkude siirdamine.
English: Since Zalmoxis has been granted a conditional approval, the company that markets Zalmoxis will provide the results of an ongoing study in high-risk acute leukaemia patients.
Estonian: Et Zalmoxis kiideti heaks tingimuslikult, esitab Zalmoxist turustav ettevõte suure riskiga ägeda leukeemiaga patsientidel toimuva uuringu tulemused.
English: It is not intended to provide practical advice on how to use Zalmoxis.
Estonian: Hindamisaruandes ei anta Zalmoxise kasutamise praktilisi nõuandeid.
English: What information is still awaited for Zalmoxis?
Estonian: Mis teavet Zalmoxise kohta veel oodatakse?
English: For the full list of restrictions and side effects reported with Zalmoxis, see the package leaflet.
Estonian: Zalmoxise kohta teatatud piirangute ja kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Before receiving an HSCT, the patient will have received treatment to remove existing cells from the bone marrow, including cancer cells and immune cells.
Estonian: Enne vereloome tüvirakkude siirdamist on patsiendid saanud ravi, et eemaldada luuüdist olemasolevad rakud, sealhulgas vähi- ja immuunrakud.
English: When using Zalmoxis, this can be treated with ganciclovir or valganciclovir.
Estonian: Zalmoxise kasutamisel saab seda ravida gantsikloviiri või valgantsikloviiriga.
English: Because the number of patients undergoing haploidentical HSCT is low, Zalmoxis was designated an ‘orphan medicine' (a medicine used in rare diseases) on 20 October 2003.
Estonian: Et haploidentset vereloome tüvirakkude siirdamist vajavate patsientide arv on väike, nimetati Zalmoxis 20. oktoobril 2003 harvikravimiks.
English: What are the risks associated with Zalmoxis?
Estonian: Mis riskid Zalmoxisega kaasnevad?
English: If the patient develops graftversus-host disease, ganciclovir or valganciclovir is given, which kills the T cells that have the suicide gene thereby treating the disease and preventing its further development.
Estonian: Kui patsiendil tekib siiriku äratõukereaktsioon, manustatakse gantsikloviiri või valgantsikloviiri, mis hävitab enesetapugeeniga Trakud, ravides nii haigust ja takistades selle edasiarenemist.
English: For practical information about using Zalmoxis, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Zalmoxise kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Zalmoxis has been investigated in a main study involving 30 patients who had haploidentical HSCT for serious blood cancers.
Estonian: Zalmoxist uuriti ühes põhiuuringus, milles osales 30 patsienti, kellele oli verevähi raskete vormide tõttu siiratud vereloome tüvirakke.
English: The T cells in Zalmoxis have a suicide gene, which makes them susceptible to the medicines ganciclovir and valganciclovir.
Estonian: Zalmoxises sisalduvatel T-rakkudel on „enesetapugeen”, mis muudab need tundlikuks gantsikloviiri ja valgantsikloviiri suhtes.
English: Zalmoxis is a medicine used as an add-on treatment in adults who have received a haematopoietic stem cell transplant (HSCT, a transplant of cells that can develop into different types of blood cells) from a partially matched donor (a so-called haploidentical transplant).
Estonian: Zalmoxis on ravim, mida kasutatakse lisaravina täiskasvanutel, kellele on siiratud vereloome tüvirakke (rakud, millest tekivad teist tüüpi vererakud) osaliselt sobivalt doonorilt (nn haploidentne siirdamine).
English: For more information about treatment with Zalmoxis, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Zalmoxisega toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: When given after transplantation, Zalmoxis helps the patient to build up their immune system and so helps to protect them from infections.
Estonian: Pärast siirdamist manustatav Zalmoxis aitab taastada patsiendi immuunsüsteemi ja kaitsta seda nakkuste eest.
English: Zalmoxis is given to help restore the patient's immune system after the transplant.
Estonian: Zalmoxist manustatakse selleks, et taastada patsiendi immuunsüsteemi pärast siirdamist.
English: Zalmoxis is used in patients who have received a haploidentical HSCT because they have serious blood cancers, such as certain leukaemias and lymphomas.
Estonian: Zalmoxist kasutatakse patsientidel, kellele on tehtud haploidentne vereloome tüvirakkude siirdamine, sest neil on verevähi rasked vormid, näiteks teatud leukeemiad ja lümfoomid.
English: The dose of Zalmoxis depends on the bodyweight of the patient.
Estonian: Zalmoxise annus sõltub patsiendi kehamassist.
English: The study will compare haploidentical HSCT followed by treatment with Zalmoxis with haploidentical HSCT containing T cells followed by treatment with cyclophosphamide (a medicine to prevent graft-versus-host disease) and with haploidentical HSCT without T cells.
Estonian: Uuringus võrreldakse haploidentset vereloome tüvirakkude siirdamist, millele järgneb ravi Zalmoxisega, T-rakke sisaldava haploidentse vereloome tüvirakkude siirdamisega, millele järgneb ravi tsüklofosfamiidiga (siiriku äratõukereaktsiooni ennetamise ravim), ja haploidentse vereloome tüvirakkude siirdamisega ilma T-rakkudeta.
English: How is Zalmoxis used?
Estonian: Kuidas Zalmoxist kasutatakse?
English: How does Zalmoxis work?
Estonian: Kuidas Zalmoxis toimib?
English: To make Zalmoxis, T cells from the HSCT donor are separated from the rest of the cells in the transplant.
Estonian: Zalmoxise valmistamiseks eraldatakse vereloome tüvirakkude doonorilt saadud T-rakud teistest siiriku rakkudest.
English: Zalmoxis has been given ‘conditional approval'.
Estonian: Zalmoxise müügiluba anti tingimuslikult.
English: What benefits of Zalmoxis have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Zalmoxise kasulikkus?
English: Zalmoxis is a type of advanced therapy medicine called a ‘somatic cell therapy product'.
Estonian: Zalmoxis on somaatilise rakuteraapia ravimite hulka kuuluv uudne ravim.
English: Zalmoxis has been shown to help restore the immune systems of patients who had haploidentical HSCT for serious blood cancers; these patients have limited treatment options and a poor prognosis.
Estonian: On tõendatud, et Zalmoxis aitab taastada immuunsüsteemi patsientidel, kellele on tehtud haploidentne vereloome tüvirakkude siirdamine verevähi raskete vormide tõttu.
English: Zalmoxis can only be obtained with a prescription and treatment is given under the supervision of a doctor who has experience in the treatment of blood cancers using HSCT.
Estonian: Ravi peab toimuma verevähi ravimisel vereloome tüvirakkude siirdamises kogenud arsti järelevalve all.
English: A flu pandemic can affect people worldwide and cause many deaths.
Estonian: Gripipandeemia võib kahjustada inimesi kogu maailmas ja põhjustada palju surmajuhtumeid.
English: Two doses of the vaccine are recommended and the child should receive the second dose at least 4 weeks after the first.
Estonian: Soovitatav on manustada kaks vaktsiiniannust ja laps peab saama teise annuse vähemalt 4 nädalat pärast esimest.
English: It should be given in an officially declared pandemic and according to official guidance.
Estonian: Seda tohib manustada ametlikult välja kuulutatud pandeemia korral ja lähtuvalt ametlikest suunistest.
English: It can particularly affect children who have not had seasonal flu or received flu vaccines previously.
Estonian: Eriti võib see kahjustada lapsi, kellel ei ole varem olnud hooajalist grippi või kes ei ole varem gripivaktsiine saanud.
English: This helps to protect against the flu that the virus causes.
Estonian: See aitab kaitsta viiruse põhjustatud gripi eest.
English: The dose is one spray (0.1 ml) into each nostril.
Estonian: Annus on üks pihustatav doos (0,1 ml) kumbagi ninasõõrmesse.
English: Most people will not have come into contact with it and therefore will not have built up protection (‘immunity') against it.
Estonian: Enamik inimesi ei ole selle tüvega kokku puutunud, mistõttu neil puudub selle vastu kaitse (immuunsus).
English: A vaccine against a specific disease ‘teaches' the immune system (the body's natural defences) to defend itself against the disease.
Estonian: Konkreetse haiguse vastane vaktsiin n-ö õpetab immuunsüsteemi (organismi looduslikke kaitsemehhanisme) kaitsma organismi haiguse eest.
English: This vaccine is intended to help with the management of a future pandemic.
Estonian: Selle vaktsiini eesmärk on aidata ohjata tulevast pandeemiat.
English: A flu pandemic occurs when a new strain of flu virus appears that can spread easily because people have no immunity (protection) against it.
Estonian: Gripipandeemia tekib, kui ilmub uus gripiviiruse tüvi, mis võib kergesti levida, sest selle vastu puudub immuunsus (kaitse).
English: The results were similar to those from three other studies involving 170 adults given pandemic preparedness vaccines containing similar types of bird flu virus, such as H7N9 and H7N7, instead of H5N1.
Estonian: Tulemused olid sarnased kolme muu uuringu tulemustega, milles 170 täiskasvanule manustati imitatsioonvaktsiine, mis sisaldasid H5N1 tüve asemel linnugripiviiruse sarnaseid tüüpe, näiteks tüvesid H7N9 ja H7N7.
English: When a child is given the vaccine, the immune system recognises the weakened virus in the vaccine as foreign and makes antibodies against it.
Estonian: Kui lapsele manustatakse vaktsiini, peab immuunsüsteem nõrgestatud viirust võõraks ja tekitab selle vastu antikehi.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) noted that preparing for a potential flu pandemic in children and adolescents meets an important medical need.
Estonian: Komitee märkis, et potentsiaalseks gripipandeemiaks valmistumine lastel ja noorukitel täidab olulise meditsiinilise vajaduse.
English: In addition, there is evidence indicating that the vaccine can protect against different strains of H5N1 virus.
Estonian: Lisaks tõendavad andmed, et vaktsiin tekitab kaitse H5N1 viiruse eri tüvede eest.
English: However, in a pandemic, it might be appropriate to give it to children with allergies if facilities for medical treatment of severe allergic reactions are immediately available.
Estonian: Pandeemia korral võib olla asjakohane manustada vaktsiini allergiaga lastele, kui on olemas raskete allergiliste reaktsioonide ravi võimalused.
English: The full EPAR for Pandemic influenza vaccine H5N1 AstraZeneca can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst vaktsiini Pandemic influenza vaccine H5N1 AstraZeneca kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Testing this pandemic preparedness vaccine helps to predict how people will react to the vaccine at the time of a pandemic, when the virus strain in the vaccine will be replaced by a weakened version of the actual strain causing the pandemic.
Estonian: Imitatsioonvaktsiini uuringud aitavad prognoosida, kuidas inimesed reageerivad vaktsiinile pandeemia ajal, mil vaktsiinis olev viirusetüvi asendatakse pandeemiat tegelikult põhjustava tüve nõrgestatud variandiga.
English: It is not possible to prepare a vaccine for a future pandemic because the strain of the pandemic flu virus is not known in advance.
Estonian: Tulevase pandeemia jaoks ei ole võimalik valmistada konkreetset vaktsiini, sest pandeemiat põhjustav gripiviiruse tüvi ei ole ette teada.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Pandemic influenza vaccine H5N1 MedImmune on 20 May 2016.
Estonian: Euroopa Komisjon andis vaktsiini Pandemic influenza vaccine H5N1 MedImmune müügiloa, mis kehtib kogu Euroopa Liidus, 20. mail 2016.
English: Pandemic influenza vaccine H5N1 AstraZeneca must not generally be given to children who have had a severe allergic reaction to any of the substances in the vaccine including gelatin and gentamicin or to children who have had a severe allergic reaction to eggs or egg proteins, such as ovalbumin.
Estonian: Vaktsiini Pandemic influenza vaccine H5N1 AstraZeneca ei tohi üldiselt manustada lastele, kellel on olnud raske allergiline reaktsioon vaktsiini mis tahes koostisaine, sealhulgas želatiini ja gentamütsiini suhtes, ega ka lastele, kellel on olnud raske allergiline reaktsioon muna või munavalkude, näiteks ovalbumiini suhtes.
English: Because a new pandemic live attenuated vaccine cannot be tested in children, the benefit of this vaccine in children was predicted from studies in adults and from studies of similar live attenuated flu vaccines in children.
Estonian: Et uue pandeemia nõrgestatud elusvaktsiini ei saa lastel uurida, prognoositakse neil kasulikkust täiskasvanute uuringute ja sarnaste nõrgestatud elusvaktsiinidega lastel tehtud uuringute põhjal.
English: This means that there is more evidence to come about the medicine, which the company is required to provide.
Estonian: See tähendab, et ettevõte peab esitama vaktsiini kohta veel andmeid.
English: Instead, a pandemic preparedness vaccine can be made to contain a bird flu virus strain that could potentially cause a future pandemic.
Estonian: Selle asemel valmistada imitatsioonvaktsiini sellisest linnugripiviiruse tüvest, mis võib tulevikus potentsiaalselt pandeemiat põhjustada.
English: Pandemic influenza vaccine H5N1 AstraZeneca is a vaccine developed to protect children aged between 12 months and 18 years against influenza (flu) during a flu pandemic.
Estonian: Pandemic influenza vaccine H5N1 AstraZeneca on vaktsiin, mis on välja töötatud 12 kuu kuni 18 aasta vanuste laste kaitsmiseks gripi eest gripipandeemia ajal.
English: Pandemic influenza vaccine H5N1 AstraZeneca contains live, attenuated (weakened) influenza A virus A/Vietnam/1203/2004 (H5N1) strain.
Estonian: Pandemic influenza vaccine H5N1 AstraZeneca sisaldab A-gripiviiruse A/Vietnam/1203/2004 (H5N1) nõrgestatud elustüve.
English: Although Pandemic influenza vaccine H5N1 AstraZeneca might increase wheezing in children aged 1 to 2 years, the risk is considered acceptable in a pandemic situation.
Estonian: Kuigi Pandemic influenza vaccine H5N1 AstraZeneca võib suurendada 1-2-aastastel lastel vilistavat hingamist, peetakse pandeemia olukorras seda riski vastuvõetavaks.
English: The most common side effects with Pandemic influenza vaccine H5N1 AstraZeneca (which may affect more than 1 in 10 people) are decreased appetite, headache, runny or stuffy nose, and feeling unwell.
Estonian: Vaktsiini Pandemic influenza vaccine H5N1 AstraZeneca kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 inimesel 10st) on isutus, peavalu, ninavoolus või ninakinnisus ning halb enesetunne.
English: The immune system will then be able to produce antibodies more quickly and in large numbers when it comes into contact with the virus again.
Estonian: Kui immuunsüsteem puutub viirusega hiljem uuesti kokku, suudab immuunsüsteem antikehi toota palju kiiremini ja suuremal hulgal.
English: This showed that antibodies against Pandemic influenza vaccine H5N1 AstraZeneca increased substantially when vaccinated adults came into contact with the virus again.
Estonian: See tõendas, et Pandemic influenza vaccine H5N1 AstraZeneca vastaste antikehade sisaldus suurenes oluliselt, kui vaktsineeritud täiskasvanud puutusid selle viirusega uuesti kokku.
English: Further studies on the effects on the vaccine in children will need to be provided once the the flu strain causing the pandemic is included in the vaccine.
Estonian: Lisauuringud vaktsiini toime kohta lastel on vaja esitada siis, kui vaktsiini lisatakse pandeemiat põhjustav gripiviiruse tüvi.
English: Thus, the CHMP decided that the benefits of the medicine in children aged 1 to 18 years are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Seega otsustas inimravimite komitee, et vaktsiini Pandemic influenza vaccine H5N1 AstraZeneca kasulikkus 1-18-aastastel lastel on suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini müügiloa.
English: In addition, the company presented extensive supportive data from large studies and from clinical practice on how well other similar pandemic and seasonal live attenuated influenza A vaccines work in children.
Estonian: Lisaks esitas ettevõte suurtest uuringutest ja kliinilisest praktikast pärinevad ulatuslikud toetavad andmed selle kohta, kuidas sarnased pandeemilised ja hooajalised A-gripiviiruse nõrgestatud elusvaktsiinid lastel toimivad.
English: This is further supported by data in children given similar seasonal and pandemic live attenuated flu vaccines in large studies and in clinical practice.
Estonian: Seda järeldust toetavad ka andmed, mida koguti laste kohta, kellele on suurtes uuringutes ja kliinilises praktikas manustatud sarnaseid hooajalise ja pandeemilise gripiviiruse nõrgestatud elusvaktsiine.
English: In those who received the second vaccine 3 weeks to 5 years after vaccination with Pandemic influenza vaccine H5N1 AstraZeneca, antibodies increased 4-fold in 73% (8 out of 11) of the individuals compared with 10% of the individuals who had not been previously vaccinated with Pandemic influenza vaccine H5N1 AstraZeneca.
Estonian: 73%-l uuritavatest (8 inimest 11st), kellele manustati teist vaktsiini 3 nädalat kuni 5 aastat pärast vaktsineerimist vaktsiiniga Pandemic influenza vaccine H5N1 AstraZeneca, suurenes antikehade hulk 4 korda, samas kui vaid 10%-l vaktsiiniga Pandemic influenza vaccine H5N1 AstraZeneca vaktsineerimata inimestest suurenes antikehade hulk 4 korda.
English: Previously known as Pandemic influenza vaccine H5N1 MedImmune
Estonian: Varasem nimetus Pandemic influenza vaccine H5N1 MedImmune
English: Since Pandemic influenza vaccine H5N1 AstraZeneca has been granted a conditional approval, the company that markets Pandemic influenza vaccine H5N1 AstraZeneca will conduct studies to gather more information on its effectiveness and side effects during its use in a pandemic as well as its shelf life.
Estonian: Et Pandemic influenza vaccine H5N1 AstraZeneca kiideti heaks tingimuslikult, korraldab vaktsiini turustav ettevõte uuringud, et koguda lisateavet vaktsiini efektiivsuse ja kõrvalnähtude kohta pandeemia ajal kasutamisel ning vaktsiini kõlblikkusaja kohta.
English: The name of the medicine was changed to Pandemic influenza vaccine H5N1 AstraZeneca on 24 May 2017.
Estonian: Vaktsiini nimetus muudeti 24. mail 2017 nimetuseks Pandemic influenza vaccine H5N1 AstraZeneca.
English: Three main studies involving 107 adults found that Pandemic influenza vaccine H5N1 AstraZeneca was able to prepare the immune system to defend itself against the H5N1 virus strain in individuals who had never come into contact with it. Antibodies against this type of vaccine are not easy to measure.
Estonian: Kolmes põhiuuringus (107 täiskasvanut) leiti, et Pandemic influenza vaccine H5N1 AstraZeneca tekitas immuunsüsteemis kaitse viirusetüve H5N1 eest isikutel, kes ei olnud selle tüvega varem kokku puutunud.
English: What measures are being taken to ensure the safe and effective use of Pandemic influenza vaccine H5N1 AstraZeneca?
Estonian: Mis meetmed võetakse, et tagada vaktsiini Pandemic influenza vaccine H5N1 AstraZeneca ohutu ja efektiivne kasutamine?
English: For practical information about using Pandemic influenza vaccine H5N1 AstraZeneca, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate vaktsiini Pandemic influenza vaccine H5N1 AstraZeneca kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pandemic influenza vaccine H5N1 AstraZeneca have been included in the summary of product characteristics and the package leaflet.
Estonian: Vaktsiini Pandemic influenza vaccine H5N1 AstraZeneca ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: However, a second vaccine that acts in a different way is able to make antibodies that can be measured easily.
Estonian: Lihtsam on mõõta teistmoodi toimiva vaktsiini antikehade tootmise võimet.
English: What is Pandemic influenza vaccine H5N1 AstraZeneca and what is it used for?
Estonian: Mis on Pandemic influenza vaccine H5N1 AstraZeneca ja milleks seda kasutatakse?
English: This is a summary of the European public assessment report (EPAR) for Pandemic influenza vaccine H5N1 AstraZeneca.
Estonian: See on vaktsiini Pandemic influenza vaccine H5N1 AstraZeneca Euroopa avaliku hindamisaruande kokkuvõte.
English: For more information about prevention of influenza with Pandemic influenza vaccine H5N1 AstraZeneca, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate vaktsiini Pandemic influenza vaccine H5N1 AstraZeneca kasutamise kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Other information about Pandemic influenza vaccine H5N1 AstraZeneca
Estonian: Muu teave vaktsiini Pandemic Influenza Vaccine H5N1 AstraZeneca kohta
English: It is not intended to provide practical advice on how to use Pandemic influenza vaccine H5N1 AstraZeneca.
Estonian: Hindamisaruandes ei anta vaktsiini Pandemic influenza vaccine H5N1 AstraZeneca kasutamise praktilisi nõuandeid.
English: The vaccine is expected to protect children against pandemic flu, on the basis of data obtained with this vaccine in adults.
Estonian: Lähtudes vaktsiini kohta täiskasvanutel kogutud andmetest, kaitseb see pandeemilise gripi eest eeldatavalt ka lapsi.
English: Why is Pandemic influenza vaccine H5N1 AstraZeneca approved?
Estonian: Miks Pandemic influenza vaccine H5N1 AstraZeneca heaks kiideti?
English: pandemic influenza vaccine (H5N1) (live attenuated, nasal)
Estonian: Pandemic influenza vaccine H5N1 AstraZeneca pandeemilise gripi vaktsiin (H5N1) (nõrgestatud elusvaktsiin, nasaalne)
English: For the full list of all side effects reported with Pandemic influenza vaccine H5N1 AstraZeneca, see the package leaflet.
Estonian: Vaktsiini Pandemic influenza vaccine H5N1 AstraZeneca kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: What information is still awaited for Pandemic influenza vaccine H5N1 AstraZeneca?
Estonian: Mis teavet vaktsiini Pandemic influenza vaccine H5N1 AstraZeneca kohta veel oodatakse?
English: Pandemic influenza vaccine H5N1 AstraZeneca is a pandemic preparedness vaccine.
Estonian: Pandemic influenza vaccine H5N1 AstraZeneca on retseptivaktsiin.
English: What are the risks associated with Pandemic influenza vaccine H5N1 AstraZeneca?
Estonian: Mis riskid vaktsiiniga Pandemic Influenza vaccine H5N1 AstraZeneca kaasnevad?
English: How does Pandemic influenza vaccine H5N1 AstraZeneca work?
Estonian: Kuidas Pandemic influenza vaccine H5N1 AstraZeneca toimib?
English: Pandemic influenza vaccine H5N1 AstraZeneca is available as a nasal spray.
Estonian: Vaktsiini Pandemic influenza vaccine H5N1 AstraZeneca turustatakse ninaspreina.
English: Pandemic influenza vaccine H5N1 AstraZeneca has been given ‘conditional approval'.
Estonian: Vaktsiini Pandemic influenza vaccine H5N1 AstraZeneca müügiluba anti tingimuslikult.
English: How is Pandemic influenza vaccine H5N1 AstraZeneca used?
Estonian: Kuidas vaktsiini Pandemic influenza vaccine H5N1 AstraZeneca kasutatakse?